Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 5,538 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 5,538 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $60.71, for a total transaction of $336,211.98. Following the sale, the insider owned 15,437 shares in the company, valued at $937,180.27. This represents a 26.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, May 19th, Jonathan Zalevsky sold 199 shares of Nektar Therapeutics stock. The shares were sold at an average price of $65.51, for a total transaction of $13,036.49.

Nektar Therapeutics Price Performance

NKTR stock opened at $60.92 on Thursday. Nektar Therapeutics has a 52-week low of $8.27 and a 52-week high of $109.00. The company’s 50 day simple moving average is $73.67 and its 200-day simple moving average is $62.18. The firm has a market capitalization of $2.06 billion, a P/E ratio of -7.24 and a beta of 1.13.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The company had revenue of $10.86 million during the quarter, compared to analyst estimates of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. Sell-side analysts predict that Nektar Therapeutics will post -9.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on NKTR. HC Wainwright upped their price objective on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Piper Sandler upped their price objective on shares of Nektar Therapeutics from $105.00 to $192.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. TD Cowen began coverage on shares of Nektar Therapeutics in a research note on Tuesday, March 17th. They issued a “buy” rating on the stock. BTIG Research upped their price objective on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Finally, Wedbush dropped their price objective on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Nektar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $149.63.

Institutional Trading of Nektar Therapeutics

Several large investors have recently added to or reduced their stakes in NKTR. AQR Capital Management LLC grew its position in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after acquiring an additional 2,807,595 shares in the last quarter. Farallon Capital Management LLC bought a new stake in Nektar Therapeutics in the third quarter worth approximately $45,008,000. Two Seas Capital LP bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth $31,506,000. Prosight Management LP bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth $23,450,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Nektar Therapeutics by 446.9% during the 3rd quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock worth $24,708,000 after buying an additional 354,842 shares during the period. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.